Previous 10 | Next 10 |
PhaseBio Pharmaceuticals (PHAS) -14% premarket after pricing 16M common stock at $3.50/share, for gross proceeds of ~$56M.Underwriters' over-allotment an additional 2.4M shares.Offering is expected to close on March 22. For further details see: PhaseBio shares down on equity r...
PhaseBio Pharmaceuticals (PHAS) says it has started an underwritten public offering of its common share. Price, size and other terms have not been yet determined. Press Release For further details see: PhaseBio Pharmaceuticals initiates stock offering
PhaseBio Pharmaceuticals (PHAS) rose 14% to $4.57 this morning after Needham raised its price target to street high $19 from $18.Needham analyst Chad Messer is maintaining his buy rating due to the rapid enrollment in the phase 3 REVERSE-IT trial of its lead candidate, bentracimab, ...
PhaseBio Pharmaceuticals (PHAS) rose 3.2% after Needham raised price target to street high $19.Developing story ... For further details see: PhaseBio Pharmaceuticals gains after Needham raises PT to street high
PhaseBio Pharmaceuticals (PHAS): Q4 GAAP EPS of -$1.03 misses by $0.36.Cash and cash equivalents of $28.1MPress Release For further details see: PhaseBio Pharmaceuticals EPS misses by $0.36
Update on Phase 3 REVERSE-IT trial - enrollment ahead of schedule Provides overview of bentracimab development program during virtual Investor & Analyst Day, March 15, 2021, 12 – 2 pm ET Announced commercial supply agreement with BioVectra to support...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
PhaseBio Pharmaceuticals (PHAS) and BioVectra, a global contract development and manufacturing organization ((CDMO)) announce a commercial scale supply agreement for the production of bentracimab. Under the terms of the agreement, BioVectra will provide its integrated CDMO services for the ma...
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, and BioVectra Inc., an innovative global contract development and manufacturing organization (C...
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that the company will be participating in two upcoming virtual investor confere...
News, Short Squeeze, Breakout and More Instantly...
PhaseBio Pharmaceuticals Inc. Company Name:
PHAS Stock Symbol:
NASDAQ Market:
Bidding Process and Auction Projected to Conclude December 2022 PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced that...
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today reported financial results for the second quarter ended June 30, 2022, and provided an upd...